In the holiday rush, there were some fun science stories I was unable to get to other than the 2022 breakthrough of the year celebrating the ongoing JWST expedition. Now that we're back from celebrating with friends and family, let's check out some of what we missed!

As human beings with trillions of cells, each of which has their associated millions of copies of myriad proteins and other biological molecules, it’s something of a miracle that enough of the molecules bump together at the right times to keep us alive and functional. In addition to our own cells, we also coexist with microscopic neighbors, including various beneficial bacteria, while fending off pathogens like disease-causing bacteria, viruses, protozoans, and fungi. We often consider the bacteria and viruses in most human diseases, which invoke our immune systems to fight them to keep us healthy, but it also makes sense that the fungi can affect us as well, a topic in cancer research that is gaining attention.

Cancer remains one of the most prevalent and deadly diseases affecting humanity. According to the Centers For Disease Control, cancer was the second leading cause of death in 2020 for Americans behind heart disease. The American Cancer Society projects at least 600,000 deaths due to cancer each year, despite the fact that mortality continues to decrease each year. The majority of these deaths are from advanced cancer, which are cancers that do not respond well to treatment and therefore cannot be cured. It is when the advanced cancer progresses to a point where it can escape the primary tumor site, a process known as metastasis, that the prognosis becomes grim.

The cell cycle is a series of phases that takes place in a cell as it grows and divides. The cell spends most of its time in interphase. During this interphase the cell grows, replicates its chromosomes, and prepares for cell division. Once the cell leaves interphase, it will undergo the process of mitoses and start divining in order to create daughter cells. These new daughter cells will then enter their own interphase and begin a new round of the cell cycle. The cell cycle and its cues are of the utmost importance, because without the cues the cells can either multiply continuously, forming masses, or will not multiply. These cues are cyclins which controls the cell cycle progression.

The tumor is an abnormal tissue mass formed when cells divide and grow excessively within the body. Tumors can be benign (not cancerous) or malignant (cancerous). Benign tumors may become larger but do not spread to nearby tissue or other parts of the body. Malignant tumors, on the other hand, can spread nearby to tissue and can also be transmitted to other parts of the body through the blood and or lymphatic system.1 But we are no strangers to tumors and how the develop.

On the other hand, many of us aren’t as familiar with a tumor’s environment. Tumor progression is profoundly affected by the subtle interaction of tumor cells with immune and non-immune cells within their environment. In particular, the interactions with the immune cell component of a tumor are fundamental in determining whether primary tumors are eradicated, metastasized, or established by dormant micro metastases.3 The environment that a tumor grows in is also much more complex than one would think because of its highly variable cell composition, large number of proteins, and structures involved in tumor formation.

This being said, tumor microenvironment includes:
• Heterogeneous populations of cancer cells
• A variety of resident and osmotic host cells
• Secretion factors
• Extracellular matrix proteins

A healthy immune system requires a series of checkpoints to ensure self tolerance and prevent damage to other tissues during immune response. Binding of costimulatory signal transduction molecules (such as CD28, ICOS, GITR) on T cells to their receptors (such as CD80/CD86, ICOSL, GITRL) on antigen presenting cells (APCs) may contribute to T cell activation. However, in some states, inhibitory signals of T cell activation and response occur during the involvement of T cell receptors. These signals are generated by proteins involved in immune checkpoints (eg, PD-1, CTLA-4, TIM-3, and LAG3). Usually PD-1 and CTLA-4 immunological checkpoint proteins are upregulated in T cells infiltrating tumors and bind to their respective ligands, PD-L1 (ligand B7-H1)/PD-L2 (ligand B7- DC) and CD80/86, and down-regulate T cell responses. Immunological checkpoint ligands are often upregulated in cancer cells as a means of evading immune detection. Therefore, immunotherapy by blocking immunological checkpoint protein activation of anti-tumor immunity has become a popular research subject for cancer therapy.